期刊文献+

小胃肠间质瘤的临床病理学特征 被引量:3

Clinicopathological features of small gastrointestinal stromal tumors
下载PDF
导出
摘要 目的 探讨小胃肠间质瘤(small gastrointestinal stromalt umors,sGIST)的临床病理学特征。方法 回顾性分析21例sGIST的临床病理学及免疫表型特征,对比分析非sGIST,并进行随访。结果 21例sGIST中女性7例,男性14例,中位年龄63岁,直径0.5-1.5cm,主要发生于胃,全部为梭形细胞型,其中9例同时伴有胃肠道恶性肿瘤。与非sGIST相比,sGIST很少出现肿瘤内出血、坏死、黏膜侵犯、溃疡及核分裂,复发风险明显低于非sGIST;免疫组化标记p53、Ki-67及肿瘤内微血管密度(microvascular density,MVD)明显低于非sGIST,差异有统计学意义(P〈0.05)。结论 sGIST可与胃肠道恶性肿瘤同时伴发,免疫组化标记p53、Ki-67及MVD均低于非sGIST,其预后较好。 Purpose To assess the clinical and pathological features of small gastrointestinal stromal tumours (sGIST). Methods To reevaluated the clinical, histological and immunohistochemical parameters of 21 sGISTs. The standard immunohistochemieal panel antibodies were studied on the tumor sections. All data were compared with clinical sGIST. Results There were a total of 7 females and 14 males of sGISTs. The median age was 63 years old. The tumors were predominantly located in the stomach showing a spindle cell morphology and the tumor sizes ranged from 0. 5 cm to 1.5 cm. 9 sGISTs combined with malignant tumors, which were gastric cancer have been incidentally detected during surgery. As the lesions were small in size, with infrequent bleeding, necrosis, mucosal invasion, ulceration and less mitotic index, sGISTs reoccurred less compared with clinical sGIST, p53, Ki-67 labeling index and microvascular density (MVD) in sGIST were significantly lower than clinical sGIST (P 〈 0.05 ). Conclusion sGIST may occure with digestive tract cancer synchronously, p53, Ki-67 labeling index and MVD were lower than clinical GIST, which means better prognosis.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2016年第12期1334-1337,1342,共5页 Chinese Journal of Clinical and Experimental Pathology
关键词 胃肿瘤 胃肠间质瘤 小胃肠间质瘤 微血管密度 预后 gastric neoplasms gastrointestinal stromal turnouts small gastrointestinal stromal tumours microvascular density prognosis
  • 相关文献

参考文献2

二级参考文献42

  • 1贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:73
  • 2詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:85
  • 3Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009, 20 Suppl 4:64-67.
  • 4Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol, 2002, 33(5):459-465.
  • 5Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol, 2005, 29( 1 ) : 52-68.
  • 6Miettinen M, Lasota J. KIT ( CD117 ) : a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol, 2005, 13 (3) :205-220.
  • 7Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol, 2004, 22(18) : 3813-3825.
  • 8Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med, 2006, 130(10) : 1466-1478.
  • 9Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008, 39 (10): 1411-1419.
  • 10DeMatteo RK, Owzar KR, Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase Ⅲ trial ACOSOG Z9001. ASCO Annual Meetings Proceedings Part Ⅰ. J Clin Oncol, 2007, 25(18 Suppl) : 10079.

共引文献117

同被引文献14

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部